Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

NIH

Sponsor class

Conditions

Mesothelioma
Neoplasms
Stomach Neoplasms
Pancreatic Neoplasms
Ovarian Neoplasms
Lung Neoplasms
Thymus Neoplasms
Colonic Neoplasms

Interventions

DEVICE: mesothelin expression testing
BIOLOGICAL: TNhYP217 CAR T Cells
DRUG: fludarabine
DRUG: cyclophosphamide

Sponsor

National Cancer Institute (NCI)